Antipsychotic drugs and catecholamine synapses. Summary of the session.
D014150:Antipsychotic Agents / Q000494:pharmacology*; D001480:Basal Ganglia Diseases / Q000517:prevention & control; D001921:Brain / Q000378:metabolism*; D002090:Butyrophenones / Q000494:pharmacology; D002395:Catecholamines / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D004357:Drug Synergism; D006801:Humans; D008032:Limbic System / Q000378:metabolism; D008781:Methyltyrosines / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use; D010640:Phenothiazines; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter / Q000378:metabolism; D012110:Reserpine / Q000494:pharmacology; D013378:Substantia Nigra / Q000378:metabolism; D013569:Synapses / Q000378:metabolism*; D009435:Synaptic Transmission
D014150:Antipsychotic Agents; D002090:Butyrophenones; D002395:Catecholamines; D018492:Dopamine Antagonists; D008781:Methyltyrosines; D010276:Parasympatholytics; D010640:Phenothiazines; D011955:Receptors, Drug; D017981:Receptors, Neurotransmitter; D012110:Reserpine; D004298:Dopamine; D009638:Norepinephrine